Is intravitreal dexamethasone implant a better choice than anti-VEGF therapy to treat complications of RVO in the retina?

Main Article Content

Katarzyna Michalska-Małecka
Dorota Śpiewak

Abstract

Retinal vein occlusion (RVO) is a retinal vein disease whose complications can lead to decreased visual acuity and even blindness. The most common cause of decreased visual acuity during RVO is a chronic cystoid macular edema. The therapy involves medications with proven efficacy from the anti-VEGF group: ranibizumab, aflibercept, off-label bevacizumab and corticosteroids: dexamethasone in the form of a prolonged-release implant, fluocinolone, and off-label triamcinolone, characterized by short half-life. Scientific reports and clinical trials confirm the efficacy of anti-VEGF drugs and corticosteroids in the treatment of RVO. Therapy should be selected individually for each patient, including accompanying diseases, both systemic and local ailments. Anti-VEGF drugs and corticosteroids improve the retinal and choroidal morphology and restore the function of the retina by improving its sensitivity; confirmed in the microperimetric examination, which translates into improved visual acuity.


Anti-VEGF therapy is associated with the necessity of reinjection, especially in the case of recurrence of macular edema and decreased visual acuity, which may result in the possibility of a reduced response to the medicine being used. In this situation, it is recommended to switch to another anti-VEGF drug or to a dexamethasone treatment.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Michalska-Małecka K, Śpiewak D. Is intravitreal dexamethasone implant a better choice than anti-VEGF therapy to treat complications of RVO in the retina?. Ophthatherapy [Internet]. 2019Jun.30 [cited 2024Mar.28];6(2):112-9. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/940
Section
Articles

References

1. Gao L, Zhou L, Tian C et al. Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis. BMC Ophthalmology. 2019; 19(1): 8.
2. Laouri M, Chen E, Looman M et al. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011; 25(8): 981-8.
3. Yagi H, Sumino H, Aoki T et al. Impaired blood rheology is associated with endothelial dysfunction in patients with coronary risk factors. Clin Hemorheol Microcirc. 2016; 62(2): 139-50.
4. Zhang Y, Yao Z, Kaila N et al. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology. 2014; 121(11): 2237-46.
5. Noma H, Funatsu H, Mimura T et al. Inflammatory factors in major and macular branch retinal vein occlusion. Ophthalmologica. 2012; 227(3): 146-52.
6. Damasceno EF, Neto AM, Damasceno NA et al. Branch retinal vein occlusion and anabolic steroids abuse in young bodybuilders. Acta Ophthalmologica. 2009; 87(5): 580-1.
7. Kaiser PK. Steroids for branch retinal vein occlusion. Am J Ophthalmol. 2005; 139(6): 1095-6.
8. Proenca Pina J, Turki K, Labreuche J et al. Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal Dexamethasone Implants. J Ophthalmol. 2016; 2016: 6016491.
9. Kim M. Usefulness of anti-vascular endothelial growth factor combined with dexamethasone implant for retinal vein occlusion. Clin Interv Aging. 2016; 11: 1451-3.
10. Pommier S, Meyer F, Guigou S et al. Long-Term Real-Life Efficacy and Safety of Repeated Ozurdex(R) Injections and Factors Associated with Macular Edema Resolution after Retinal Vein Occlusion: The REMIDO 2 Study. Ophthalmologica. 2016; 236(4): 186-92.
11. Guler HA, Ornek N, Ornek K et al. Effect of dexamethasone intravitreal implant (Ozurdex(R)) on corneal endothelium in retinal vein occlusion patients: Corneal endothelium after dexamethasone implant injection. BMC Ophthalmol. 2018; 18(1): 235.
12. Altunel O, Goktas A, Duru N et al. The Effect of Age on Dexamethasone Intravitreal Implant (Ozurdex(R)) Response in Macular Edema Secondary to Branch Retinal Vein Occlusion. Seminars Ophthalmol. 2018; 33(2): 179-84.
13. Singer MA, Jansen ME, Tyler L et al: Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series. Clin Ophthalmol. 2017; 11: 31-8.
14. Altunel O, Duru N, Goktas A et al. Evaluation of foveal photoreceptor layer in eyes with macular edema associated with branch retinal vein occlusion after ozurdex treatment. Int Ophthalmol .2017; 37(2): 333-9.
15. Arifoglu HB, Duru N, Altunel O et al. Short-term effects of intravitreal dexamethasone implant (OZURDEX(R)) on choroidal thickness in patients with naive branch retinal vein occlusion. Arq Bras Oftalmol. 2016; 79(4): 243-6.
16. Bandello F, Parravano M, Cavallero E et al. Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex(R)) for retinal vein occlusion. Ophthalmic Res. 2015; 53(4): 207-16.
17. Winterhalter S, Lux A, Maier AK et al. Microperimetry as a routine diagnostic test in the follow-up of retinal vein occlusion? Graefes Arch Clin Exp Ophthalmol. 2012; 250(2): 175-83.
18. Campochiaro PA, Hafiz G, Mir TA et al. Pro-Permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; the Ozurdex for Retinal Vein Occlusion (ORVO) Study. Am J Ophthalmol. 2015; 160(2): 313-21.e319.
19. Garweg JG, Zandi S. Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex(R)) in its treatment. Graefes Arch Clin Exp Ophthalmol. 2016; 254(7): 1257-65.
20. Tservakis I, Koutsandrea C, Papaconstantinou D et al. Safety and efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors. Curr Drug Saf. 2015; 10(2): 145-51.
21. Yuksel B, Karti O, Celik O et al. Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion. Clin Exp Optom. 2018; 101(1): 116-22.
22. Ozkaya A, Tarakcioglu HN, Tanir I. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes. Optom Vis Sci. 2018; 95(12): 1149-54.
23. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014; 7(2): 167-80.
24. Qian T, Zhao M, Xu X. Comparison between anti-VEGF therapy and corticosteroid or laser therapy for macular oedema secondary to retinal vein occlusion: A meta-analysis. J Clin Pharm Ther. 2017; 42(5): 519-29.
25. Pielen A, Buhler AD, Heinzelmann SU et al. Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa. J Ophthalmol. 2017; 2017: 5831682.
26. Campochiaro PA, Sophie R, Pearlman J et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014; 121(1): 209-19.
27. Berger AR, Cruess AF, Altomare F et al. Optimal Treatment of Retinal Vein Occlusion: Canadian Expert Consensus. Ophthalmologica. 2015; 234(1): 6-25.
28. Bajor A, Pielen A, Danzmann L. [Retinal Vein Occlusion – Which Treatment When?]. Klin Monbl Augenheilkund. 2017; 234(10): 1259-65.
29. Pulido JS, Flaxel CJ, Adelman RA et al. Retinal Vein Occlusions Preferred Practice Pattern((R)) Guidelines. Ophthalmology. 2016; 123(1): P182-208.
30. Feltgen N, Pielen A: [Retinal vein occlusion: Therapy of retinal vein occlusion]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2015; 112(8): 695-704; quiz 705-696.
31. Chang-Lin JE, Attar M, Acheampong AA et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011; 52(1): 80-6.
32. Park SP, Ahn JK. Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. Clin Exp Ophthalmol. 2008; 36(9): 831-5.